INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Eli Lilly and Company
Back to Newsroom
🏢Organization Dossier

Eli Lilly and Company

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

4 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Markets & Equities Just now (11:45 AM IST)

Lilly’s Full Retatrutide Data Raises the Stakes in the Next Obesity Drug Race

Eli Lilly has released full phase 3 data on retatrutide, intensifying competition in the fast-growing obesity drug market and reinforcing investor focus on next-generation weight-loss therapies. The results add to a broader pipeline battle that is increasingly centered on efficacy, durability, and potential benefits beyond weight reduction.

By RDU Global Wire5 min read
Global Health & BiotechJust now (03:00 PM IST)

Foghorn Cuts 40% of Staff After Lilly Ends Cancer Pact on Data Concerns

Foghorn Therapeutics is laying off about 40% of its workforce after Eli Lilly terminated a cancer drug collaboration that had been a key strategic and financial pillar for the biotech company. The collapse of the partnership, reportedly tied to concerns over data quality, has intensified pressure on Foghorn’s pipeline and sent its shares sharply lower as investors reassess the company’s near-term prospects.

5 min readRead →
Global Markets & EquitiesJust now (03:47 AM IST)

Eli Lilly’s Triple-G Obesity Drug Posts Strong Early Weight Loss Even at Lowest Dose

Eli Lilly said its closely watched obesity candidate retatrutide produced substantial weight loss in a mid-stage trial, with patients on the lowest dose losing 12.7% of body weight. The result reinforces investor expectations that next-generation incretin therapies could extend the market beyond current GLP-1 leaders and intensify competition across global healthcare equities.

5 min readRead →
Global Markets & EquitiesJust now (09:54 AM IST)

Lilly’s Latest Weight-Loss Drug Drives Up to 60-Pound Loss in Diabetes Trial

Eli Lilly said its experimental triple-agonist drug retatrutide produced striking weight loss and meaningful blood-sugar improvements in people with type 2 diabetes, adding to the company’s lead in the fast-expanding obesity and metabolic disease market. The results intensify investor focus on a drug class that could reshape treatment standards and expand the commercial race against rival therapies.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Eli Lilly and Company: